Regulation of Insulin-like Growth Factor–Mammalian Target of Rapamycin Signaling by MicroRNA in Childhood Adrenocortical Tumors

Doghman, Mabrouka; Wakil, Abeer El; Cardinaud, Bruno; Thomas, Emilie; Wang, Jinling; Zhao, Wei; Valle, Maria Helena C. Peralta-Del; Figueiredo, Bonald C.; Zambetti, Gerard P.; Lalli, Enzo

doi:10.1158/0008-5472.can-09-3970

Cited by 198 publications

(251 citation statements)

References 44 publications

Supporting

Mentioning

212

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, Batisse-Lignier and coworkers also showed that long-term mice treatment with rapamycin (an inhibitor of mTOR signaling) significantly reduced tumor size and hormonal production. These data are consistent with previous studies showing the efficacy of mTOR and dual PI3K/mTOR inhibitors to impair H295R cell proliferation both in vitro and grown as xenografts in nude mice (Doghman et al 2010, Doghman & Lalli 2012.…”

Section: Animal Models Of Metastatic Actsupporting

confidence: 93%

The next step: mechanisms driving adrenocortical carcinoma metastasis

Lalli

Luconi²

2018

Endocrine-Related Cancer

Self Cite

View full text Add to dashboard Cite

Endocrine tumors have the peculiarity to become clinically evident not only due to symptoms related to space occupation by the growing lesion, similarly to most other tumors, but also, and most often, because of their specific hormonal secretion, which significantly contributes to their pathological burden. Malignant endocrine tumors, in addition, have the ability to produce distant metastases. Here, we critically review the current knowledge about mechanisms and biomarkers characterizing the metastatic process in adrenocortical carcinoma (ACC), a rare endocrine malignancy with a high risk of relapse and metastatization even when the primary tumor is diagnosed and surgically removed at an early stage. We highlight perspectives of future research in the domain and possible new therapeutic avenues based on targeting factors having an important role in the metastatic process of ACC.

show abstract

Section: Animal Models Of Metastatic Actsupporting

confidence: 93%

The next step: mechanisms driving adrenocortical carcinoma metastasis

Lalli

Luconi²

2018

Endocrine-Related Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…PTEN is an important tumor suppressor that antagonizes PI3K activity by inhibiting the transformation of PIP2 to PIP3. In cancers, the expression of PTEN is repressed by many oncogenic miRNAs, including miR-21 [80,81] , miR-221/2 [82] , miR-301 [83] , miR-144 [84] , miR-136 [84] , and miR-19 [85] . SHIP is another lipid phosphatase that inhibits the generation of PIP3.…”

Section: Pi3k/akt Pathwaymentioning

confidence: 99%

Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy

Liang

2011

Acta Pharmacol Sin

View full text Add to dashboard Cite

The cell cycle, which is precisely controlled by a number of regulators, including cyclins and cyclin-dependent kinases (CDKs), is crucial for the life cycle of mammals. Cell cycle dysregulation is implicated in many diseases, including cancer. Recently, compelling evidence has been found that microRNAs play important roles in the regulation of cell cycle progression by modulating the expression of cyclins, CDKs and other cell cycle regulators. Herein, the recent findings on the regulation of the cell cycle by microRNAs are summarized, and the potential implications of miRNAs in anti-cancer therapies are discussed.

show abstract

“…SF-1 induces proliferation of ACC cell lines and tumour growth in vivo (Doghman et al 2009) and its increased expression has been associated with a worse prognosis (Sbiera et al 2010). SF-1 inhibitors in ACC cell lines inhibited cell proliferation associated with SF-1 overexpression along with steroid hormone oversecretion and CYP21 and CYP17 mRNA expression (Doghman et al 2010).…”

Section: Molecular Profilementioning

confidence: 99%

Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies

Angelousi¹,

Dimitriadis²,

Zografos³

et al. 2017

Endocrine-Related Cancer

View full text Add to dashboard Cite

Tumourigenesis is a relatively common event in endocrine tissues. Currently, specific guidelines have been developed for common malignant endocrine tumours, which also incorporate advances in molecular targeted therapies (MTT), as in thyroid cancer and in gastrointestinal neuroendocrine malignancies. However, there is little information regarding the role and efficacy of MTT in the relatively rare malignant endocrine tumours mainly involving the adrenal medulla, adrenal cortex, pituitary, and parathyroid glands. Due to the rarity of these tumours and the lack of prospective studies, current guidelines are mostly based on retrospective data derived from surgical, locoregional and ablative therapies, and studies with systemic chemotherapy. In addition, in many of these malignancies the prognosis remains poor with individual patients responding differently to currently available treatments, necessitating the development of new personalised therapeutic strategies. Recently, major advances in the molecular understanding of endocrine tumours based on genomic, epigenomic, and transcriptome analysis have emerged, resulting in new insights into their pathogenesis and molecular pathology. This in turn has led to the use of novel MTTs in increasing numbers of patients. In this review, we aim to present currently existing and evolving data using MTT in the treatment of adrenal, pituitary and malignant parathyroid tumours, and explore the current utility and effectiveness of such therapies and their future evolution.

show abstract

Regulation of Insulin-like Growth Factor–Mammalian Target of Rapamycin Signaling by MicroRNA in Childhood Adrenocortical Tumors

Cited by 198 publications

References 44 publications

The next step: mechanisms driving adrenocortical carcinoma metastasis

The next step: mechanisms driving adrenocortical carcinoma metastasis

Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy

Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies

Contact Info

Product

Resources

About